Has Santen Pharmaceutical (TSE:4536) Earned Its 56% Rise And Buyback Support?

Résumé détaillé

Santen Pharmaceutical has logged a strong run in recent years, and the question now is whether that climb is fully explained by what the business earns. With the stock price…

Santen Pharmaceutical has logged a strong run in recent years, and the question now is whether that climb is fully explained by what the business earns. With the stock price moving ahead, the key issue is how closely that market enthusiasm lines up with Santen Pharmaceutical's earnings power.

The issue now is whether Santen Pharmaceutical's current share price is justified by its earnings when set against the Fair Ratio benchmark.

If you are weighing Santen Pharmaceutical's 56.1% three year return against its earnings story, it can help to compare it with a wider set of stocks filtered by 21 high quality undervalued stocks.

The P/E ratio is a good fit for Santen Pharmaceutical because earnings remain the main anchor for how this kind of healthcare group is priced. On this measure, the stock trades on about 16.7x earnings, which is mildly above the Pharmaceuticals industry average of roughly 15.4x but below the broader peer group on around 20.7x. That places Santen Pharmaceutical in a middle ground where investors are paying some premium to the sector, yet not as much as for many comparable companies.

The Fair Ratio, which reflects what a tailored P/E might look like after factoring in growth prospects, profitability, scale and risk, comes out higher than where the shares currently trade. Because the board has approved a sizeable buyback that aims to retire almost 5% of outstanding stock, the market is still valuing Santen Pharmaceutical on a lower earnings multiple than this framework would suggest despite that capital return plan. For anyone weighing the recent 3 year share price gain against current earnings power, the gap to this Fair Ratio indicates a P/E that may still be on the undervalued side relative to the company's fundamentals.

Simply Wall St Narratives expand on the P/E and Fair Ratio analysis for Santen Pharmaceutical by explaining which combinations of future growth, margins and earnings would need to occur for the share price to appear meaningfully…

A…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.